Topics

This margetuximab data might be the number one thing I’m interested in seeing at #ASCO19 this year. https://www.globenewswire.com/news-release/2019/05/01/1813789/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-First-Quarter-2019-Financial-Res

05:53 EDT 2 May 2019 | Brad Loncar

This margetuximab data might be the number one thing I’m interested in seeing at this year. https://www.globenewswire.com/news-release/2019/05/01/1813789/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-First-Quarter-2019-Financial-Results.html …

Original Article: This margetuximab data might be the number one thing I’m interested in seeing at #ASCO19 this year. https://www.globenewswire.com/news-release/2019/05/01/1813789/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-First-Quarter-2019-Financial-Res

NEXT ARTICLE

More From BioPortfolio on "This margetuximab data might be the number one thing I’m interested in seeing at #ASCO19 this year. https://www.globenewswire.com/news-release/2019/05/01/1813789/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-First-Quarter-2019-Financial-Res"

Quick Search